J&J beats quarterly sales and profit estimates on cancer drug sales

The good, the bad and the ugly of GLP-1s: study

Chinese biotech Ascentage aims for $134M IPO

Zimbabwe fears US withdrawal from WHO will hit HIV/AIDS programs

Beta Bionics targets up to $616 mln valuation in US IPO

Milena Sullivan elevated to lead policy practice at Avalere

Health literacy in 2025

FDA approves standalone use of J&J’s ketamine-derived depression treatment

US FDA puts clinical hold on Atara’s trials for cancer cell therapies

Trump orders US exit from the World Health Organization

Sionna, Odyssey join growing 2025 IPO class as analysts forecast ‘muted’ market

Sage sues partner Biogen after unsolicited takeover offer

Exclusive: Kennedy played key role in Gardasil vaccine case against Merck

Boehringer suffers Phase III schizophrenia fail, legal parry by HHS

HHS announces 15 additional drugs selected for Medicare Drug Price Negotiations

Looking beyond obesity, Amgen wins colorectal cancer expansion for Lumakras

Uniphar appoints industry leader, Isaac Batley, as global head of scientific communications

Outgoing FDA chief flags online weight loss drug dangers

US appeals court reinstates pause on generic version of Novartis’ Entresto

Pharma digs in on changes it wants from Trump administration

WHO seeks $1.5 billion for global health emergencies

Lilly’s I&I push gains momentum with Omvoh expansion

After letter to commissioner, FDA finally gives Vanda reason for rejection, chance for hearing

HHS says Vertex is ‘grasping at straws’ with Casgevy fertility suit

JPM Day 3: AbbVie, Gilead, GSK and Dyne